The influence of oracin on reduction and toxicity of doxorubicin in hepatocytes and mammary epithelial cells MCF-10A

References

• Adamcová M, Gersl V, Hrdina R, Melka M, Mazurová Y, Vávrová J, Palicka V, Kokstein Z. (1999). Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits. J Cancer Res Clin Oncol 125:268–274.
   PubMed Web of Science ®Google Scholar
• Ax W, Soldan M, Koch L, Maser E. (2000). Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol 59:293–300.
   PubMed Web of Science ®Google Scholar
• Bae JY, Ahn SJ, Han W, Noh DY. (2007). Peroxiredoxin I and II inhibit H2O2-induced cell death in MCF-7 cell lines. J Cell Biochem 101:1038–1045.
   PubMed Web of Science ®Google Scholar
• Barnabé N, Marusak RA, Hasinoff BB. (2003). Prevention of doxorubicin-induced damage to rat heart myocytes by arginine analog nitric oxide synthase inhibitors and their enantiomers. Nitric Oxide 9:211–216.
   PubMed Web of Science ®Google Scholar
• Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM, Relling MV, Robison LL, Sklar CA, Stovall M, Bhatia S. (2008). Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112:2789–2795.
   PubMed Web of Science ®Google Scholar
• Berry MN, Edwards AM, Barritt GJ. (1991). Isolatedhepatocytespreparation, properties and applications. Laboratorytechniques in biochemistry and molecularbiology. Amsterdam: Elsevier Science.
   Google Scholar
• Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, Moreira PI. (2009). Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 16:3267–3285.
   PubMed Web of Science ®Google Scholar
• Davies KJA, Doroshow JH. (1986). Radox cycling of anthracyclines by cardiac mitochondria. The Journal of biological chemistry 7:3060–3067.
   Google Scholar
• Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. (1996). MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 148:313–319.
   PubMedGoogle Scholar
• Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, Fernando A, Glaysher S, Di Palma S, Johnson P, Somers SS, Toh S, Higgins B, Lamont A, Gulliford T, Hurren J, Yiangou C, Cree IA. (2005). Cancer cell adaptation to chemotherapy. BMC Cancer 5:78.
   PubMed Web of Science ®Google Scholar
• Durak I, Canbolat O, Kaçmaz M, Ozgen G, Oztürk HS. (1998). Antioxidant interferences in superoxide dismutase activity methods using superoxide radical as substrate. Clin Chem Lab Med 36:407–408.
   PubMed Web of Science ®Google Scholar
• Erenpreisa J, Cragg MS. (2001). Mitotic death: a mechanism of survival? A review. Cancer Cell Int 1:1.
   PubMedGoogle Scholar
• Fischer D, Seifert M, Becker S, Ludders D, Cordes T, Reichrath J et al. (2007). 25-Hydroxyvitamin D3 1α-hydroxylase splice variants in breast cell lines between MCF-7 and MCF-10. Cancer Genomics Proteomics 4:295–300.
   PubMedGoogle Scholar
• Gajewski E, Gaur S, Akman SA, Matsumoto L, van Balgooy JN, Doroshow JH. (2007). Oxidative DNA base damage in MCF-10A breast epithelial cells at clinically achievable concentrations of doxorubicin. Biochem Pharmacol 73:1947–1956.
   PubMed Web of Science ®Google Scholar
• Gavelová M, Hladíková J, Vildová L, Novotná R, Vondrácek J, Krcmár P, Machala M, Skálová L. (2008). Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells. Chem Biol Interact 176:9–18.
   PubMed Web of Science ®Google Scholar
• Gersl V, Mazurová Y, Bajgar J, Melka M, Hrdina R, Palicka V. (1996). Lack of cardiotoxicity of a new antineoplastic agent, a synthetic derivative of indenoisochinoline: comparison with daunorubicin in rabbits. Arch Toxicol 70:645–651.
   PubMed Web of Science ®Google Scholar
• Hanušová V, Boušová I, Skálová L. (2011). Possibilities to increase the effectiveness of doxorubicin in cancer cells killing. Drug Metab Rev 43:540–557.
   PubMed Web of Science ®Google Scholar
• Hanusová V, Králová V, Schröterová L, Trilecová L, Pakostová A, Skálová L. (2010). The effectiveness of oracin in enhancing the cytotoxicity of doxorubicin through the inhibition of doxorubicin deactivation in breast cancer MCF-7 cells. Xenobiotica 40:681–690.
   PubMed Web of Science ®Google Scholar
• Kalender S, Kalender Y, Ates A, Yel M, Olcay E, Candan S. (2002). Protective role of antioxidant vitamin E and catechin on idarubicin-induced cardiotoxicity in rats. Braz J Med Biol Res 35:1379–1387.
   PubMed Web of Science ®Google Scholar
• Kalender Y, Yel M, Kalender S. (2005). Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effects of vitamin E and catechin. Toxicology 209:39–45.
   PubMed Web of Science ®Google Scholar
• Kassner N, Huse K, Martin HJ, Gödtel-Armbrust U, Metzger A, Meineke I, Brockmöller J, Klein K, Zanger UM, Maser E, Wojnowski L. (2008). Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos 36:2113–2120.
   PubMed Web of Science ®Google Scholar
• Klucar J, Al-Rubeai M. (1997). G2 cell cycle arrest and apoptosis are induced in Burkitt’s lymphoma cells by the anticancer agent oracin. FEBS Lett 400:127–130.
   PubMed Web of Science ®Google Scholar
• Lewis MJ, Wiebe JP, Heathcote JG. (2004). Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 4:27.
   PubMed Web of Science ®Google Scholar
• Lopez de Cerain A, Marin A, Idoate MA, Tunon MT, Bello J. (1999). Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoral versus normal tissues. Eur J Cancer 35:320–324.
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229.
   PubMed Web of Science ®Google Scholar
• Mordente A, Minotti G, Martorana GE, Silvestrini A, Giardina B, Meucci E. (2003). Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications. Biochem Pharmacol 66:989–998.
   PubMed Web of Science ®Google Scholar
• Ng R, Better N, Green MD. (2006). Anticancer agents and cardiotoxicity. Semin Oncol 33:2–14.
   PubMed Web of Science ®Google Scholar
• O’Connor R, O’Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O’Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J. (2007). A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother Pharmacol 59:79–87.
   PubMed Web of Science ®Google Scholar
• Oppermann U. (2007). Carbonyl reductases, the complex relationships of mammalian carbonyl-and quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol Toxicol 47:293–322.
   PubMed Web of Science ®Google Scholar
• Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. (2004). Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 30:181–191.
   PubMed Web of Science ®Google Scholar
• Sereno M, Brunello A, Chiappori A, Barriuso J, Casado E, Belda C, de Castro J, Feliu J, González-Barón M. (2008). Cardiac toxicity: old and new issues in anti-cancer drugs. Clin Transl Oncol 10:35–46.
   PubMed Web of Science ®Google Scholar
• Simunek T, Stérba M, Popelová O, Adamcová M, Hrdina R, Gersl V. (2009). Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61:154–171.
   PubMed Web of Science ®Google Scholar
• Skarydová L, Skarka A, Novotná R, Zivná L, Martin HJ, Wsól V, Maser E. (2009). Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin. Toxicology 264:52–60.
   PubMed Web of Science ®Google Scholar
• Trédan O, Galmarini CM, Patel K, Tannock IF. (2007). Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99:1441–1454.
   PubMed Web of Science ®Google Scholar
• Václavíková R, Kondrová E, Ehrlichová M, Boumendjel A, Kovár J, Stopka P, Soucek P, Gut I. (2008). The effect of flavonoid derivatives on doxorubicin transport and metabolism. Bioorg Med Chem 16:2034–2042.
   PubMed Web of Science ®Google Scholar